OrthoPediatrics Corp. reported a net revenue of $59.4 million for the first quarter of 2026, marking a 13% increase from $52.4 million in the same period of 2025. The growth was primarily driven by strong sales in the trauma and deformity correction segment, which rose to $43.0 million, up from $37.9 million, and the scoliosis category, which increased to $15.4 million from $13.7 million. Despite the revenue growth, the company recorded a net loss of $10.7 million, slightly higher than the $10.7 million loss reported in the prior year, resulting in a net loss per share of $(0.45) compared to $(0.46) in 2025.
The company's operating expenses also saw an increase, totaling $51.7 million for the quarter, up from $49.2 million a year earlier. Sales and marketing expenses rose by 11% to $18.5 million, attributed to higher sales commissions and increased unit sales. General and administrative expenses increased by 2% to $31.0 million, driven by additional personnel for clinic expansions and small-scale acquisitions. Research and development expenses decreased slightly by 5% to $2.2 million, reflecting the timing of product development activities.
In terms of operational developments, OrthoPediatrics has continued to expand its geographic footprint and product offerings. The company operates over 50 orthotic and prosthetic clinics in the U.S. and has established a presence in international markets, including recent acquisitions in Europe and Brazil. The company’s total assets decreased to $502.2 million as of March 31, 2026, down from $508.6 million at the end of 2025, primarily due to a reduction in cash and short-term investments.
Looking ahead, OrthoPediatrics anticipates continued investment in its product portfolio and expansion into new markets, which may lead to ongoing operating losses in the near term. The company has a cash balance of $12.2 million and short-term investments of $36.6 million, which it believes will support its operations for the next twelve months. The company is also focused on enhancing its sales and distribution infrastructure to capitalize on the estimated $6.2 billion global pediatric orthopedic market opportunity.
About ORTHOPEDIATRICS CORP
OrthoPediatrics Corp. specializes in designing, developing, and marketing pediatric-specific orthopedic implants, instruments, and braces for trauma, deformity correction, scoliosis, and sports medicine. Serving hospitals worldwide, it supports pediatric surgeons through dedicated sales, clinical education, and research collaborations. Its comprehensive product portfolio addresses unmet needs in children’s orthopedic care, leveraging innovation, strategic acquisitions, and a focus on improving young patients' outcomes.
About 10-Q Filings
A 10-Q form is an important financial report that public companies in the United States must submit every three months. It gives a clear picture of a company's financial health and recent performance.
Key points about the 10-Q:
- Frequency: Companies file it three times a year, covering the first three quarters. The fourth quarter is covered in a more comprehensive annual report.
-
Content: It includes:
- Financial statements showing the company's current financial position
- Updates from management on the performance and projections of the business
- Information about potential risks the company faces
- Details on how the company is run internally
- Deadline: Must be filed within 40 or 45 days after the quarter ends, depending on the size of the company.
Our Methodology
AssetRoom is committed to providing timely summaries of news from public companies. We use AI to generate these summaries quickly, but they are not reviewed by human experts.
Our method:
- Data Collection: We continuously monitor for new filings (currently limited to US-listed stocks).
- AI-Powered Analysis: Our advanced AI system processes each filing, identifying key information and extracting relevant data.
- Summary Generation: The AI creates a concise, easy-to-understand summary of the filing, highlighting the most important points.
- Publication: The summary is immediately published on our platform, allowing users instant access to the latest information.
- Email users: We distribute round-up emails according to our users preferences, keeping them in the loop with the companies they follow.
Feedback & Corrections
Spot an error or have a suggestion? Contact us.